A comment on tirzepatide versus glucagon‐like peptide‐1 receptor agonists and heart rate with regard to ‘Impact of a dual glucose‐dependent insulinotropic peptide/glucagon‐like peptide‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis’

Diabetes, Obesity and MetabolismEarly View LETTER TO THE EDITOR A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to ‘Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis’ Ronald M. Goldenberg MD, Corresponding Author Ronald M. Goldenberg MD ronaldgoldenberg@gmail.com orcid.org/0000-0002-1788-3255 LMC Diabetes & Endocrinology, Concord, Ontario, Canada Correspondence Ronald M. Goldenberg, MD, LMC Diabetes & Endocrinology, 1600 Steeles Avenue West #5, Concord, ON, L4K 4M2, Canada. Email: ronaldgoldenberg@gmail.comSearch for more papers by this author Ronald M. Goldenberg MD, Corresponding Author Ronald M. Goldenberg MD ronaldgoldenberg@gmail.com orcid.org/0000-0002-1788-3255 LMC Diabetes & Endocrinology, Concord, Ontario, Canada Correspondence Ronald M. Goldenberg, MD, LMC Diabetes & Endocrinology, 1600 Steeles Avenue West #5, Concord, ON, L4K 4M2, Canada. Email: ronaldgoldenberg@gmail.comSearch for more papers by this author First published: 28 November 2023 https://doi.org/10.1111/dom.15381Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Open Research PEER REVIEW The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15381. DATA AVAILABILITY STATEMENT Data sharing is not applicable to this article as no new data were created. REFERENCES 1Yang Y, He L, Liu P, et al. Impact of a dual glucose-dependent insulinotropic peptide / glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: a systematic review and pairwise and network meta-analysis. Diabetes Obes Metab. 2023; 1-9. doi:10.1111/dom.15342 10.1111/dom.15342 Web of Science®Google Scholar 2Alexander JT, Staab EM, Wan W, et al. The longer-term benefits and harms of glucagon-like Peptide-1 receptor agonists: a systematic review and meta-analysis. J Gen Intern Med. 2022; 37(2): 415-438. 10.1007/s11606-021-07105-9 PubMedWeb of Science®Google Scholar 3Wice BM, Reeds DN, Tran HD, et al. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes. 2012; 61(7): 1793-1800. 10.2337/db11-1451 CASPubMedWeb of Science®Google Scholar 4Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018; 392(10160): 2180-2193. 10.1016/S0140-6736(18)32260-8 CASPubMedWeb of Science®Google Scholar 5Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022; 10(6): 418-429. 10.1016/S2213-8587(22)00085-7 CASPubMedWeb of Science®Google Scholar 6Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022; 10(9): 623-633. 10.1016/S2213-8587(22)00188-7 CASPubMedWeb of Science®Google Scholar 7Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385(6): 503-515. 10.1056/NEJMoa2107519 CASPubMedWeb of Science®Google Scholar 8Pucino F. Center for Drug Evaluation and Research, Clinical Review NDA 215866 (Ttirzepatide). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000MedR.pdf (accessed: 21 October 2023) Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation